Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 2,418 | |
| Option exercise | 2 | 4,577 | |
| Other acquisition / disposition | 5 | 3,421,116 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
13 Form 4 filings on record, the earliest from Aug 11, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| WEXFORD CAPITAL LP - 10% Owner | Other | Common Stock | 3,355,111 | $0.00 | - | |
| WEXFORD CAPITAL LP - 10% Owner | Other | Common Stock | 22,710 | $3.95 | $90K | |
| Arthur H. Amron - Director | Other | Common Stock | 17,749 | $0.00 | - | |
| Arthur H. Amron - Director | Other | Common Stock | 2,836 | $0.00 | - | |
| Arthur H. Amron - Director | Other | Common Stock | 22,710 | $3.95 | $90K | |
| WEXFORD CAPITAL LP - 10% Owner | Option exercise | Common Stock | 812 | $3.60 | $3K | |
| WEXFORD CAPITAL LP - 10% Owner | Option exercise | Stock Option (Right to Buy) | 3,765 | $0.00 | - | |
| Arthur H. Amron - Director | Grant or award | Common Stock | 2,418 | $0.00 | - | |
| Arthur H. Amron - Director | Grant or award | Common Stock | 3,574 | $0.00 | - | |
| Option exercise | Common Stock | 120,000 | $1.44 | $173K | ||
| Option exercise | Stock Option (right to buy) | 120,000 | $0.00 | - | ||
| Option exercise | Common Stock | 68,861 | $1.71 | $118K | ||
| Option exercise | Stock Option (right to buy) | 68,861 | $0.00 | - | ||
| Arthur H. Amron - Director | Grant or award | Common Stock | 3,610 | $0.00 | - | |
| Grant or award | Stock Option (right to buy) | 4,000 | $0.00 | - | ||
| Lisa Marie Nettis - Director | Grant or award | Common Stock | 1,622 | $0.00 | - | |
| Oliver J. Spandow - Director | Grant or award | Common Stock | 8,036 | $0.00 | - | |
| Arthur H. Amron - Director | Grant or award | Common Stock | 5,391 | $0.00 | - | |
| Lisa Marie Nettis - Director | Grant or award | Stock Option (right to buy) | 13,229 | $0.00 | - |
NEPHROS INC (NEPH) had 4 insider filings in the last 90 days, with the most recent on 2026-09-16. The full record for NEPH runs to 13 Form 4 filings, the earliest from 2025-08-11. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of NEPH were filed in the last 90 days.
No insider sales of NEPH were filed in the last 90 days.
This page tracks NEPH Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add NEPH to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.